A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD 
1.
Are the results valid? * randomized? yes * double-blinded? yes * were groups similar? yes * all patients accounted for? yes
2.
What were the results: n = 142 (Donepezil grp); n = 144 (Placebo grp) Primary Scale GBS -the decline in the donepezil group was approximately 50% of the placebo group, p < .05 GBS-I seemed to be the scale with the best effect (p < .05) GBS-ADL, GBS-E, GBS-S -no statistical difference 
Secondary Scale

3.
Will the results help me? * ~92% of patients tolerated the 10 mg dose, ~10% had to decrease back to 5 mg * ~95% compliance in both groups * 33.1% withdrew in the donepezil group, 32.6% in the placebo group * difficult to assess clinical significance
